Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas

Ajay P. Singh, Subhash Chauhan, Sangeeta Bafna, Sonny L. Johansson, Lynette M. Smith, Nicolas Moniaux, Ming Fong Lin, Surinder K. Batra

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

BACKGROUND. Mucins are considered important markers for early diagnosis and targeted therapy due to their aberrant and unique expression pattern during malignant progression of carcinomas. Recent findings have provided substantial evidence for the involvement of transmembrane mucins, MUC1 and MUC4, in altered cell signaling, tumor growth, and metastasis. METHODS. Immunohistochemical analyses were performed on prostate tumor tissues for expression profiling of the two transmembrane mucins, MUC1 and MUC4. In cancer cell lines, the expression was studied by RT-PCR and immunoblot analyses. Cells were treated with DNA-methylase and histone-deacetylase inhibitors to examine the implication of epigenetic mechanism(s) in MUC4 regulation. RESULTS. The expression of MUC4 was significantly downregulated in prostate cancer tissues (n = 38, P = 0.0026) compared to normal/benign prostatic hyperplastic regions. A faint to moderate staining was observed in 26.3% cases of cancer, while 84.2% cases of adjacent normal were positive for MUC4 with moderate to strong staining in most cases. Similar observations were made in immortalized normal prostate epithelial and cancer cell lines. MUC1 also showed a reduced expression in prostate tumor tissues; however, its expression was comparable in all normal prostate epithelial and cancer cell lines. Interestingly, we also found that epigenetic mechanism(s) might be implicated in MUC4 gene silencing. CONCLUSIONS. Our data suggest that MUC4 downregulation may be of significance for diagnostic applications in prostate cancer.

Original languageEnglish (US)
Pages (from-to)421-429
Number of pages9
JournalProstate
Volume66
Issue number4
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Mucins
Prostate
Prostatic Neoplasms
Carcinoma
Neoplasms
Epigenomics
Cell Line
Down-Regulation
Epithelial Cells
Staining and Labeling
Histone Deacetylase Inhibitors
Gene Silencing
Early Diagnosis
Neoplasm Metastasis
Polymerase Chain Reaction
DNA
Growth

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Singh, A. P., Chauhan, S., Bafna, S., Johansson, S. L., Smith, L. M., Moniaux, N., ... Batra, S. K. (2006). Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas. Prostate, 66(4), 421-429. https://doi.org/10.1002/pros.20372

Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas. / Singh, Ajay P.; Chauhan, Subhash; Bafna, Sangeeta; Johansson, Sonny L.; Smith, Lynette M.; Moniaux, Nicolas; Lin, Ming Fong; Batra, Surinder K.

In: Prostate, Vol. 66, No. 4, 01.03.2006, p. 421-429.

Research output: Contribution to journalArticle

Singh, AP, Chauhan, S, Bafna, S, Johansson, SL, Smith, LM, Moniaux, N, Lin, MF & Batra, SK 2006, 'Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas', Prostate, vol. 66, no. 4, pp. 421-429. https://doi.org/10.1002/pros.20372
Singh, Ajay P. ; Chauhan, Subhash ; Bafna, Sangeeta ; Johansson, Sonny L. ; Smith, Lynette M. ; Moniaux, Nicolas ; Lin, Ming Fong ; Batra, Surinder K. / Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas. In: Prostate. 2006 ; Vol. 66, No. 4. pp. 421-429.
@article{8b872b11939f48a2a92e5c1e48f8cfd5,
title = "Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas",
abstract = "BACKGROUND. Mucins are considered important markers for early diagnosis and targeted therapy due to their aberrant and unique expression pattern during malignant progression of carcinomas. Recent findings have provided substantial evidence for the involvement of transmembrane mucins, MUC1 and MUC4, in altered cell signaling, tumor growth, and metastasis. METHODS. Immunohistochemical analyses were performed on prostate tumor tissues for expression profiling of the two transmembrane mucins, MUC1 and MUC4. In cancer cell lines, the expression was studied by RT-PCR and immunoblot analyses. Cells were treated with DNA-methylase and histone-deacetylase inhibitors to examine the implication of epigenetic mechanism(s) in MUC4 regulation. RESULTS. The expression of MUC4 was significantly downregulated in prostate cancer tissues (n = 38, P = 0.0026) compared to normal/benign prostatic hyperplastic regions. A faint to moderate staining was observed in 26.3{\%} cases of cancer, while 84.2{\%} cases of adjacent normal were positive for MUC4 with moderate to strong staining in most cases. Similar observations were made in immortalized normal prostate epithelial and cancer cell lines. MUC1 also showed a reduced expression in prostate tumor tissues; however, its expression was comparable in all normal prostate epithelial and cancer cell lines. Interestingly, we also found that epigenetic mechanism(s) might be implicated in MUC4 gene silencing. CONCLUSIONS. Our data suggest that MUC4 downregulation may be of significance for diagnostic applications in prostate cancer.",
author = "Singh, {Ajay P.} and Subhash Chauhan and Sangeeta Bafna and Johansson, {Sonny L.} and Smith, {Lynette M.} and Nicolas Moniaux and Lin, {Ming Fong} and Batra, {Surinder K.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1002/pros.20372",
language = "English (US)",
volume = "66",
pages = "421--429",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Aberrant expression of transmembrane mucins, MUCI and MUC4, in human prostate carcinomas

AU - Singh, Ajay P.

AU - Chauhan, Subhash

AU - Bafna, Sangeeta

AU - Johansson, Sonny L.

AU - Smith, Lynette M.

AU - Moniaux, Nicolas

AU - Lin, Ming Fong

AU - Batra, Surinder K.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - BACKGROUND. Mucins are considered important markers for early diagnosis and targeted therapy due to their aberrant and unique expression pattern during malignant progression of carcinomas. Recent findings have provided substantial evidence for the involvement of transmembrane mucins, MUC1 and MUC4, in altered cell signaling, tumor growth, and metastasis. METHODS. Immunohistochemical analyses were performed on prostate tumor tissues for expression profiling of the two transmembrane mucins, MUC1 and MUC4. In cancer cell lines, the expression was studied by RT-PCR and immunoblot analyses. Cells were treated with DNA-methylase and histone-deacetylase inhibitors to examine the implication of epigenetic mechanism(s) in MUC4 regulation. RESULTS. The expression of MUC4 was significantly downregulated in prostate cancer tissues (n = 38, P = 0.0026) compared to normal/benign prostatic hyperplastic regions. A faint to moderate staining was observed in 26.3% cases of cancer, while 84.2% cases of adjacent normal were positive for MUC4 with moderate to strong staining in most cases. Similar observations were made in immortalized normal prostate epithelial and cancer cell lines. MUC1 also showed a reduced expression in prostate tumor tissues; however, its expression was comparable in all normal prostate epithelial and cancer cell lines. Interestingly, we also found that epigenetic mechanism(s) might be implicated in MUC4 gene silencing. CONCLUSIONS. Our data suggest that MUC4 downregulation may be of significance for diagnostic applications in prostate cancer.

AB - BACKGROUND. Mucins are considered important markers for early diagnosis and targeted therapy due to their aberrant and unique expression pattern during malignant progression of carcinomas. Recent findings have provided substantial evidence for the involvement of transmembrane mucins, MUC1 and MUC4, in altered cell signaling, tumor growth, and metastasis. METHODS. Immunohistochemical analyses were performed on prostate tumor tissues for expression profiling of the two transmembrane mucins, MUC1 and MUC4. In cancer cell lines, the expression was studied by RT-PCR and immunoblot analyses. Cells were treated with DNA-methylase and histone-deacetylase inhibitors to examine the implication of epigenetic mechanism(s) in MUC4 regulation. RESULTS. The expression of MUC4 was significantly downregulated in prostate cancer tissues (n = 38, P = 0.0026) compared to normal/benign prostatic hyperplastic regions. A faint to moderate staining was observed in 26.3% cases of cancer, while 84.2% cases of adjacent normal were positive for MUC4 with moderate to strong staining in most cases. Similar observations were made in immortalized normal prostate epithelial and cancer cell lines. MUC1 also showed a reduced expression in prostate tumor tissues; however, its expression was comparable in all normal prostate epithelial and cancer cell lines. Interestingly, we also found that epigenetic mechanism(s) might be implicated in MUC4 gene silencing. CONCLUSIONS. Our data suggest that MUC4 downregulation may be of significance for diagnostic applications in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33644790089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644790089&partnerID=8YFLogxK

U2 - 10.1002/pros.20372

DO - 10.1002/pros.20372

M3 - Article

VL - 66

SP - 421

EP - 429

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -